PDCD1 and neoplasm: Consistent with LLC tumors being refractory to PD-1 blockade, anti-PD-1 mAb monotherapy (150 μg/mouse, intraperitoneal, 15 min before each CDA injection) did not slow LLC tumor growth (figure 3A), and had minimal survival impact (figure 3B).